Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Nyxoah SA reported robust financial and operating results for Q2 and H1 2026, driven by successful U.S. commercial execution post FDA approval of its lead product, the Genio system for treating obstructive sleep apnea. The company achieved 22% sequential revenue growth in the U.S. for Q2 and secured $110 million in financing to expand its commercia…